Bo Yu1, Rani Fritz2, Xianhong Xie3, Abdissa Negassa3, Sangita Jindal2, Mario Vega2, Erkan Buyuk2. 1. Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington. Electronic address: by26@uw.edu. 2. Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, New York; Montefiore's Institute for Reproductive Medicine and Health, Hartsdale, New York. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Abstract
OBJECTIVE: To assess the impact of using donor sperm in assisted reproductive technology (ART) cycles on perinatal outcomes. DESIGN: Historical cohort study. SETTING: US national database from the Society of Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) from 2012 to 2013. PATIENT(S): Patients undergoing the first fresh autologous ART cycle using either donor or partner sperm. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Miscarriage, preterm birth, low birthweight rates. RESULTS: A total of 134,710 fresh autologous ART cycles were evaluated from the SART CORS database. Following exclusion criteria and after restricting to the first cycle, 2,123 donor sperm and 42,799 partner sperm ART cycles were included in the final analyses. After adjusting for all confounding variables (including maternal age, race, body mass index, smoking status, gravidity, history of preterm birth, highest follicle stimulating hormone count, blastocyst transfer percentage, total embryo transferred, and etiology of infertility), no statistically significant differences in miscarriage rates, preterm births, very preterm births, low birthweight, and very low birthweight were observed. Birthweight was significantly lower in the partner sperm group than in the donor sperm group (3,292 ± 601 and 3,233 ± 592 g in donor and partner sperm groups, respectively, adjusted P value 0.003); however, this small absolute difference (adjusted effect estimate 42 g, 95% CI 14.7-70.9) does not carry clinical significance. CONCLUSIONS: The use of donor sperm in fresh autologous ART cycles was not associated with increased miscarriage, preterm births, or low birthweights, as compared to cycles using partner sperm. This information can be used in patient counseling to reassure patients using donor sperm in ART cycles.
OBJECTIVE: To assess the impact of using donor sperm in assisted reproductive technology (ART) cycles on perinatal outcomes. DESIGN: Historical cohort study. SETTING: US national database from the Society of Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) from 2012 to 2013. PATIENT(S): Patients undergoing the first fresh autologous ART cycle using either donor or partner sperm. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Miscarriage, preterm birth, low birthweight rates. RESULTS: A total of 134,710 fresh autologous ART cycles were evaluated from the SART CORS database. Following exclusion criteria and after restricting to the first cycle, 2,123 donor sperm and 42,799 partner sperm ART cycles were included in the final analyses. After adjusting for all confounding variables (including maternal age, race, body mass index, smoking status, gravidity, history of preterm birth, highest follicle stimulating hormone count, blastocyst transfer percentage, total embryo transferred, and etiology of infertility), no statistically significant differences in miscarriage rates, preterm births, very preterm births, low birthweight, and very low birthweight were observed. Birthweight was significantly lower in the partner sperm group than in the donor sperm group (3,292 ± 601 and 3,233 ± 592 g in donor and partner sperm groups, respectively, adjusted P value 0.003); however, this small absolute difference (adjusted effect estimate 42 g, 95% CI 14.7-70.9) does not carry clinical significance. CONCLUSIONS: The use of donor sperm in fresh autologous ART cycles was not associated with increased miscarriage, preterm births, or low birthweights, as compared to cycles using partner sperm. This information can be used in patient counseling to reassure patients using donor sperm in ART cycles.
Authors: Eileen T Samy; Yulius Y Setiady; Katsuhiro Ohno; Patcharin Pramoonjago; Colin Sharp; Kenneth S K Tung Journal: Immunol Rev Date: 2006-08 Impact factor: 12.988
Authors: Daniela Diego; Alexandra Medline; Lisa M Shandley; Jennifer F Kawwass; Heather S Hipp Journal: J Assist Reprod Genet Date: 2022-09-12 Impact factor: 3.357